EUVIMEDEUVIMED entdecken
Crossref

Hans-Based Cell of Origin Is Not of Prognostic Significance in Diffuse Large B-Cell Lymphoma Patients: A Retrospective Single-Center Study Conducted in 326 RCHOP-Treated Patients

Marianthi Symeonidou, Stergios George Intzes, Konstantinos Zagoridis, Lazaros Karatisidis, Theodoros Mprotsis, Georgios Kanelis, Georgios Vrachiolias, Iliana Stamatiou, Zoe Bezirgiannidou, Bouse Malkots, Menelaos Papoutselis, Christoforos Roumpakis und 5 weitere

Acta Haematologica · 2025

DOI: 10.1159/000549608 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, 2025. Verfasst von Marianthi Symeonidou und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive lymphoma with dismal outcome after disease progression. Individual risk assessment can stratify patients into different treatment strategies.

Methods

We retrospectively collected data from 326 DLBCL patients treated in a single center with RCHOP from 01/2000 to 06/2023. Immunohistochemistry by Han’s algorithm was used to classify patients according to cell of origin (COO). The Kaplan-Meier estimator of survival and Cox regression analysis were used.

Results

Time to progression (TTP) and overall survival (OS) were not different according to COO. Univariate analysis reveals International Prognostic Index (IPI), b2-microglobulin ≥3.5 mg/L, bulky disease, and abnormal LDH, but not Han’s defined COO, as the strongest predictors for progression. IPI score in multivariate analysis was the only prognostic factor for OS and together with high b2-microglobulin levels were independently prognostic factors for TTP. Accordingly, b2-microglobulin ≥3.5 mg/L was an independent prognostic factor for progression both in GC (hazard ratio [HR] 0.249 [(95% CI: 0.087–0.649), p = 0.004] and non-GC DLBCL patients (HR 0.380 [95% CI: 0.177–0.813], p = 0.011).

Conclusion

COO according to Hans index is not a significant prognostic factor for DLBCL patients, but b2-microglobulin ≥3.5 mg/L and IPI 2–5 in both GC and non-GC patients can predict individually a higher risk for progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleRetrospective StudiesCyclophosphamideDoxorubicinPrednisonePrognosisVincristineMiddle AgedRituximabAgedAdultbeta 2-MicroglobulinAntibodies, Monoclonal, Murine-DerivedAged, 80 and over

Stichwörter der Autor:innen

B2-microglobulinCell of originDiffuse large B-cell lymphoma

Substanzen

CyclophosphamideDoxorubicinPrednisoneVincristineRituximabbeta 2-MicroglobulinAntibodies, Monoclonal, Murine-DerivedR-CHOP protocol

Autor:innen und Institutionen

  • Department of Hematology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece.
  • Department of Biomathematics, University of Thessaly, School of Medicine, Volos, Greece.
  • Department of Hematopathology, General Hospital of "Evagelismos", Athens, Greece.
  • Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
  • Department of Obstetrics and gynecology, Democritus University of Thrace, Alexandroupolis, Greece.
  • Department of Hematology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece, espanoud@med.duth.gr.

Zitieren

APA

Symeonidou, M., Intzes, S. G., Zagoridis, K., Karatisidis, L., Mprotsis, T., Kanelis, G., Vrachiolias, G., Stamatiou, I., Bezirgiannidou, Z., Malkots, B., Papoutselis, M., Roumpakis, C., Skendros, P., Tsikouras, P., Liapis, K., Kotsianidis, I., & Spanoudakis, E. (2025). Hans-Based Cell of Origin Is Not of Prognostic Significance in Diffuse Large B-Cell Lymphoma Patients: A Retrospective Single-Center Study Conducted in 326 RCHOP-Treated Patients. Acta Haematologica. https://doi.org/10.1159/000549608

Vancouver

Symeonidou M, Intzes SG, Zagoridis K, Karatisidis L, Mprotsis T, Kanelis G, et al. Hans-Based Cell of Origin Is Not of Prognostic Significance in Diffuse Large B-Cell Lymphoma Patients: A Retrospective Single-Center Study Conducted in 326 RCHOP-Treated Patients. Acta Haematologica. 2025. doi:10.1159/000549608

BibTeX
@article{Symeonidou2025,
  author = {Symeonidou, Marianthi and Intzes, Stergios George and Zagoridis, Konstantinos and Karatisidis, Lazaros and Mprotsis, Theodoros and Kanelis, Georgios and Vrachiolias, Georgios and Stamatiou, Iliana and Bezirgiannidou, Zoe and Malkots, Bouse and Papoutselis, Menelaos and Roumpakis, Christoforos and Skendros, Panagiotis and Tsikouras, Panagiotis and Liapis, Konstantinos and Kotsianidis, Ioannis and Spanoudakis, Emmanouil},
  title = {Hans-Based Cell of Origin Is Not of Prognostic Significance in Diffuse Large B-Cell Lymphoma Patients: A Retrospective Single-Center Study Conducted in 326 RCHOP-Treated Patients},
  journal = {Acta Haematologica},
  year = {2025},
  doi = {10.1159/000549608}
}
Kostenlos starten →